Literature DB >> 18300041

Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.

Maysaa El Sayed Zaki1, Fatma Abbas Auf, Nabieh Anwar El Ghawalby, Nirmeen Mohamed El Saddal.   

Abstract

Hepatitis C Virus (HCV) is a major etiological agent of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Fas-mediated apoptosis is the major cause of hepatocyte damage during liver disease. The present work was performed to study the fas system (Fas-FasL and soluble Fas) in chronic hepatitis C infection. Also, to correlate the degree of liver cell damage with the Fas system. The study was carried out on 45 patients positive for HCV RNA by nested RT-PCR in addition to 13 HCV negative control subjects. Wedge liver biopsies samples were obtained from patients and controls during abdominal operations for determination of cellular expression of Fas and Fas-L on hepatocytes and infiltrating lymphocytes respectively by flow cytometry. Histological activity index (HAI) was determined in chronic HCV patients. Also blood samples were taken from patients and controls for determination of sFas. There was statistically insignificant difference in Fas expression in hepatocytes of patients (P = 0.34) in comparison to control. Meanwhile, there was a statistically significant decrease in FasL expression in patients compared to control (P< 0.001) and statistically significant increase in soluble Fas in patients compared to control (P < 0.001). The HAI of liver fibrosis for all patients were within mild score with mean +/- SD 4 +/- 0.5. From this study, we could conclude that Fas system is one of the important pathways regulating the response to HCV infection. Increased serum sFas in HCV patients is accompanied by down-regulation of Fas/Fas-L expression resulting in inhibition of apoptosis in liver cells as a process for elimination of virus infected cells and this may ultimately leads to chronicity of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300041     DOI: 10.1080/08820130801897352

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

Review 1.  Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

Authors:  Pamela Valva; Daniela A Ríos; Elena De Matteo; Maria V Preciado
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

2.  Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis.

Authors:  Bo Zhang; Mintao Hu; Lihua Huang; Yunchuan Pu; Hao Pei; Zhong Hua; Shangzhi Yao
Journal:  Exp Ther Med       Date:  2014-08-08       Impact factor: 2.447

3.  Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children.

Authors:  Pamela Valva; Paola Casciato; Carol Lezama; Marcela Galoppo; Adrián Gadano; Omar Galdame; María Cristina Galoppo; Eduardo Mullen; Elena De Matteo; María Victoria Preciado
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

4.  Genetic Polymorphisms of Fas/FasL Promoter Associated with Hepatitis C cirrhosis and HCC

Authors:  Sally Abed; Mohamed El-Dosoky; Maysaa El Sayed Zaki; Mohamed EL-Shafey
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.